Xencor Enter into an Exclusive WW License Agreement with Janssen to Develop and Commercialize Plamotamab and Xmab CD28 Bispecific Antibody for B-Cell Malignancies

Shots:

• Xencor to receive $100M up front, $25M as an equity investment, ~$1.18B in milestones along with royalties on net sales of products that emerge from the collaboration. The transaction is expected to close in Q4’21
• Janssen to get exclusive development & commercialization rights for plamotamab globally as monothx. or in combination regimens. Xencor obtains an option to co-fund development costs in exchange for higher royalties & has the right to co-detail XmAb CD28 bispecific Ab combinations in the US
• The companies collaborated to expand the clinical development of plamotamab in which Janssen pay 80% & Xencor 20% of costs including SC formulation & is expected to enter a clinical trial in 2022

Click here to­ read full press release/ article | Ref: Businesswire | Image: Xencor